natgillin/translations-raw huggingface dataset:
n is 1 or 2; and X is hydrobromic acid, benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5-naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid. 
n je 1 ili 2; i X je bromovodična kiselina, benzensulfonska kiselina, kamfor sulfonska kiselina, 1,2-etan disulfonska kiselina, klorovodična kiselina, maleinska kiselina, metansulfonska kiselina, naftalen-2-sulfonska kiselina, 1,5-naftalen disulfonska kiselina, oksalna kiselina, 4-toluensulfonska kiselina ili 2,4,6-trihidroksibenzojeva kiselina.
The compound of claim 2, wherein the compound is a Form I hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. 
Spoj prema zahtjevu 2, pri čemu spoj je Oblik I soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 17.39, oko 19.45, oko 21.41, oko 23.56 i oko 27.45 stupnjeva 2-theta.
47.20 47.51 The compound of claim 2, wherein (i) the compound is a Form III hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta, or: 
Spoj prema zahtjevu 2, pri čemu (i) spoj je Oblik III soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 6.79, oko 13.36, oko 19.93, oko 20.89, oko 21.90, oko 22.70, oko 22.91 i oko 26.34 stupnjeva 2-theta, ili:
wherein (ii) the compound is a Form IV hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta, or: 
pri čemu (ii) spoj je Oblik IV soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 6.45, oko 12.96, oko 19.38, oko 19.79, oko 21.37 i oko 21.58 stupnjeva 2-theta, ili:
wherein (iii) the compound is a Form V hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta, or: 
pri čemu (iii) spoj je Oblik V soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 6.17, oko 6.99, oko 12.50, oko 14.14, oko 17.72 i oko 23.12 stupnjeva 2-theta, ili:
wherein (iv) the compound is a Form VI hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta, or: 
pri čemu (iv) spoj je Oblik VI soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 8.38, oko 9.38, oko 18.93, i oko 21.58 stupnjeva 2-theta, ili:
wherein (v) the compound is a Form VII hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. 
pri čemu (v) spoj je Oblik VII soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 15.91, oko 19.10, oko 19.53, oko 20.24, oko 22.64 i oko 25.58 stupnjeva 2-theta.
The compound of claim 2, wherein the compound is a Form VIII hydrobromic acid salt characterized by a powder X-ray diffraction pattern having peaks at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. 
Spoj prema zahtjevu 2, pri čemu spoj je Oblik VIII soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 8.79, oko 11.13, oko 19.97, oko 21.31, oko 21.56, oko 25.30 i oko 26.65 stupnjeva 2-theta.
The compound of claim 1, wherein X is camphor sulfonic acid, or: 
Spoj prema zahtjevu 1, naznačen time što X je kamfor sulfonska kiselina, ili:
The compound or composition for use according to claim 11, wherein said compound is sparing for WT EGFR, or: 
Spoj ili pripravak za upotrebu prema zahtjevu 11, naznačen time što navedeni spoj se štedi za WT EGFR, ili:
wherein the at least one mutant is an activating mutant, a deletion mutant, a point mutation, or a mutant selected from T790M, delE746-A750, L858R, G719S. 
pri čemu barem jedan mutant je aktivirajući mutant, delecijski mutant točka mutacije, ili mutant izabran od T790M, delE746-A750, L858R, G719S.
A composition according to claim 10 for use in the treatment of a mutant EGFR-mediated disorder or condition, preferably wherein the disorder or condition is a cancer. 
Pripravak prema zahtjevu 10 naznačen time što je za upotrebu za liječenje poremećaja ili stanja posredovanog sa mutantom EGFR, poželjno pri čemu poremećaj ili stanje je rak.
Administering 200 mg of the tiacumicin compound BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and 
primjenu 200 mg spoja tiakumicina BID tijekom 5 dana nakon čega slijedi 5 dana odmora i zatim 200 mg jednom dnevno tijekom daljnjih 10 dana i
administering 200 mg of the tiacumicin compound BID for 5 days followed by a single 200 mg every other day for 20 days. 
primjenu 200 mg spoja tiakumicina BID tijekom 5 dana nakon čega slijedi jednom 200 mg svaki drugi dan tijekom 20 dana.
The tiacumicin compound for use according to claim 1, characterized in that the tiacumicin compound is selected from the group consisting of tiacumicin A, tiacumicin B and analogues thereof, (dialkyltiacumicins and bromotiacumicins), tiacumicin C, tiacumicin D, tiacumicin E, tiacumicin F and lipiarmycin. 
Spoj tiakumicina za uporabu prema zahtjevu 1, naznačen time što je spoj tiakumicina odabran iz skupine koja sadrži tiakumicin A, tiakumicin B i njihove analoge, (dialkiltiakumicine i bromotiakumicine), tiakumicin C, tiakumicin D, tiakumicin E, tiakumicin F i lipiarmicin.
The tiacumicin compound for use according to each of claims 1-5, characterized in that a tablet, a suspension, a dry powder for an aqueous suspension, a dry granulate for an aqueous suspension, a film-coated tablet or a dispersible tablet is used. 
Spoj tiakumicina za uporabu prema svakom od zahtjeva 1-5, naznačen time što se koristi tableta, suspenzija, suhi prašak za vodenu suspenziju, suhi granulat za vodenu suspenziju, filmom obložena tableta ili raspadljiva tableta.
A pharmaceutical composition, comprising a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CDAD) in a patient according to a dosage regimen selected from the group consisting of: 
Farmaceutski pripravak, koji sadrži spoj tiakumicina, njegov stereoizomer, njegov polimorf ili njegov farmaceutski prihvatljiv solvat, za upotrebu u oralnom liječenju infekcija sa Clostridium difficile (CDI) ili proljeva ili bolesti povezane s Clostridium difficile (CDAD) kod pacijenta u skladu s režimom doziranja koji je odabran iz skupine koja sadrži:
The pharmaceutical composition, comprising the tiacumicin compound, for use according to claim 8, characterized in that the tiacumicin compound is selected from the group consisting of tiacumicin A, tiacumicin B and analogues thereof, (dialkyltiacumicins and bromotiacumicins), tiacumicin C, tiacumicin D, tiacumicin E, tiacumicin F and lipiarmycin. 
Farmaceutski pripravak, koji sadrži spoj tiakumicina, za uporabu prema zahtjevu 8, naznačen time što je spoj tiakumicina odabran iz skupine koja sadrži tiakumicin A, tiakumicin B i njihove analoge, (dialkiltiakumicine i bromotiakumicine), tiakumicin C, tiakumicin D, tiakumicin E, tiakumicin F i lipiarmicin.
mapping segments of DNA obtained from the bodily fluid of the pregnant individual to a plurality of polymorphism sequences, wherein the DNA was sequenced under conditions that identify the plurality of polymorphism sequences; 
mapiranje segmenata DNK dobivenih iz tjelesne tekućine trudne osobe na osnovu mnoštva polimorfizama sekvenci, pri čemu je DNK sekvencirana pod uvjetima koji identificiraju mnoštvo polimorfizama sekvenci;
The method of claim 1, further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified as being heterozygous in both the fetus and the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao heterozigotni i kod fetusa i kod trudne osobe.
The method of claim 1, further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified as being homozygous in both the fetus and the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao homozigotni i kod fetusa i kod trudne osobe.
The method of claim 1, wherein mapping the nucleic acids obtained from bodily fluid of a pregnant individual comprises mapping said segments to a database of polymorphisms. 
Postupak prema patentnom zahtjevu 1, naznačen time što mapiranje nukleinskih kiselina dobivenih iz tjelesne tekućine trudne osobe podrazumijeva mapiranje navedenih segmenata na osnovu baze podataka polimorfizama.
The method of claim 1, further comprising sequencing the DNA from the bodily fluid of pregnant individual with a nucleic acid sequencer under conditions that produce DNA segment sequences containing the polymorphism sequences. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži sekvenciranje DNK iz tjelesne tekućine trudne osobe upotrebom sekvencera nukleinskih kiselina pod uvjetima koji proizvode sekvence DNK segmenata u kojima je prisutan polimorfizam sekvenci.
The method of claim 1, wherein the mapping in (a) comprises identifying a plurality of biallelic polymorphism sequences. 
Postupak prema patentnom zahtjevu 1, naznačen time što mapiranje u (a) podrazumijeva identificiranje mnoštva bialelnih polimorfizama sekvenci.
The method of claim 1, further comprising executing program instructions on the one or more processors to automatically record the fraction of fetal of DNA as estimated in (c) in a patient medical record, stored on a computer readable medium, for the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži izvršavanje programskih uputa u okviru jednog ili više procesora radi automatskog snimanja frakcije fetusne DNK koja je procijenjena u (c) u medicinski karton trudne osobe, kao i čuvanje na mediju koji može biti očitan od pomoću računala.
• at least one insulated return mat, suited to be electrically connected to said generator in order to close the high-frequency current circuit, and wherein said mat must be placed between the patient and the supporting surface, chair or bed where the patient is positioned; 
• najmanje jednu izoliranu povratnu prostirku, pogodnu za električno spajanje s navedenim generatorom kako bi se zatvorilo krug visokofrekventne struje, te gdje navedenu prostirku treba staviti između pacijenta i nosive površine, stolice ili kreveta, gdje se nalazi pacijent;
High-frequency electro medical device according to any of the preceding claims, characterized in that it also comprises a further hand piece with a 60 mm application head and intensity of approximately 3,5 Jcm2. 
Visokofrekvencijski elektromedicinski uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što također ima dodatni ručni dio s radnom glavom veličine 60 mm i s intenzitetom od otprilike 3,5 Jcm2.
High-frequency electro medical device according to any of the preceding claims, characterized in that said generator is automatically and immediately deactivated if one or more power supply circuit/circuits is/are out of control and/or if the power amplifier absorption exceeds the maximum allowable current. 
Visokofrekvencijski elektromedicinski uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedeni generator automatski i trenutačno deaktivira ako jedan ili više krugova napajanja je ili su izvan kontrole i/ili ako apsorpcija pojačale snage prelazi najjaču dopustivu struju.
between the casing and formation. 
između kućišta i tvorbe.
A well apparatus as claimed in claim 10 or claim 11, wherein the packer (16) is provided on the casing string (12a,12b,12c,12d) adjacent to a cemented-in portion of the casing. 
Bunarska aparatura, sukladno patentnim zahtjevima 10 ili 11, naznačeno time, da je paker osiguran na kućiš noj žici (12a,12b,12c,12d) pored zacementiranog dijela kućišta.
A well apparatus as claimed in any one of claims 10 to 12, wherein the packer (16) is provided in use in the expanded configuration and acts as a permanent barrier to resist fluid flow. 
Bunarska aparatura, u skladu s bilo kojim prethodnim patentnim zahtjevom 10-12, naznačeno time, da je paker (16) osiguran u uporabi u proširenoj konfiguraciji I dijela kao trajna barijera koja onemogućuje protok tekućine.
A well apparatus as claimed in any one of claims 10 to 16, wherein the packer (16) is provided within 100m of a wellhead, optionally more within 50m, especially within 20m, and more especially within 10m. 
Bunarska aparatura, u skladu s patentnim zahtjevima 10-16, naznačeno time, da je paker (16) osiguran unutar 100m od bušotine, po izboru više od 50 m, posebno u okviru 20 m, a osobito u okviru 10 m.
is selected from hydrogen and C1-C4 alkyl. 
je odabran od vodika i C1-C4 alkila.
A compound according to Claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to Claim 10, for use in treating a disorder associated with CRM1 activity. 
Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol ili farmaceutski pripravak prema zahtjevu 10, naznačen time što je za uporabu za liječenje poremećaja povezanog s aktivnošću CRM1.
The compound for use or composition for use according to Claim 11, wherein the disorder is selected from a proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, and a respiratory disorder. 
Spoj za uporabu ili pripravak za uporabu u skladu sa zahtjevom 11, naznačen time što je poremećaj odabran od proliferativnog poremećaja, upalnog poremećaja, autoimunog poremećaja, virusne infekcije, oftalmološkog poremećaja, neurodegenerativnog poremećaja, poremećaja abnormalnog rasta tkiva, poremećaja povezanog s unosom hrane, alergija te respiratornog poremećaja.
The compound for use or composition for use according to Claim 12, wherein the disorder is cancer; optionally wherein the cancer is lymphoma. 
Spoj za uporabu ili pripravak za uporabu u skladu sa zahtjevom 12, naznačen time što je poremećaj rak; proizvoljno pri čemu rak je limfom.
The compound for use or composition for use according to Claim 11, wherein: the disorder is arthritis; 
Spoj za uporabu ili pripravak za uporabu u skladu sa zahtjevom 11, naznačen time što: poremećaj je artritis;
the disorder is obesity. 
poremećaj je pretilost;
the disorder is stroke; 
poremećaj je moždani udar;
the disorder is traumatic brain injury; or the disorder is selected from multiple sclerosis, lupus and amyotrophic lateral sclerosis. 
poremećaj je traumatska ozljeda mozga; ili poremećaj je odabran od multiple skleroze, lupusa i amiotrofne lateralne skleroze.
A pharmaceutical combination comprising a humanized antibody specifically recognizing CD38 and at least bortezomib, wherein said antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytoxicity (CDC), and wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises the amino acid sequence SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence consisting of SEQ ID NOS: 62 or 64. 
Farmaceutska kombinacija koja sadrži humanizirano protutijelo koje specifično prepoznaje CD38 i barem bortezomib, naznačena time što je navedeno protutijelo sposobno za ubijanje CD38+ stanica pomoću apoptoze, posredovane citotoksičnosti ovisne o protutijelu (ADCC), te citotoksičnosti ovisne o komplementu (CDC), i pri čemu navedeno protutijelo sadrži barem jedan teški lanac i barem jedan lagani lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline SEQ ID NO: 66, te pri čemu navedeni lagani lanac sadrži sekvencu aminokiseline koja se sastoji od SEQ ID NOS: 62 ili 64.
The combination for the use according to claim 2 wherein the antitumor efficacy of the combination is from 0 to 10% T/C, wherein T/C(%) is the ratio Median tumor volume of the treated / Median tumor volume of the control x 100. 
Kombinacija za uporabu prema zahtjevu 2 naznačena time što je antitumorska učinkovitost kombinacije je od 0 do 10% T/C, pri čemu T/C(%) je omjer medijalnog tretiranog volumena tumora / medijalni volumen tumora za kontrolu x 100.
The combination for the use according to any one of claims 2 to 4 wherein the administration of antibody specifically recognizing CD38 and bortezomib are spaced out over a period of time so as to obtain the maximum efficacy of the combination. 
Kombinacija za uporabu prema bilo kojem od zahtjeva 2 do 4 naznačena time što su primjena protutijela koje specifično prepoznaje CD38 i bortezomiba razmaknute tijekom vremenskog perioda kako bi se dobila maksimalna učinkovitost kombinacije.
a packaging material 
materijal pakiranja
a combination of a humanized antibody specifically recognizing CD38 and at least bortezomib, wherein said antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytoxicity (CDC), and wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises the amino acid sequence SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence consisting of SEQ ID NOS: 62 or 64, and 
kombinaciju humaniziranog protutijela koje specifično prepoznaje CD38 i barem bortezomib, pri čemu navedeno protutijelo je sposobno za ubijanje CD38+ stanica pomoću apoptoze, posredovane citotoksičnosti ovisne o protutijelu (ADCC), te citotoksičnosti ovisne o komplementu (CDC), i pri čemu navedeno protutijelo sadrži barem jedan teški lanac i barem jedan lagani lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline SEQ ID NO: 66, te pri čemu s navedeni lagani lanac sadrži sekvencu aminokiseline koja se sastoji od SEQ ID NOS: 62 ili 64, i
a label or package insert contained within said packaging material indicting that said combination thereof is effective for treating cancer. 
naljepnicu ili upute za upotrebu sadržane unutar navedenog materijala za pakiranje koje pokazuju da je navedena kombinacija učinkovita za liječenje raka.
A humanized antibody specifically recognizing CD38 for use in the treatment of a CD38-expressing cancer in combination with at least bortezomib, wherein said antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytoxicity (CDC), and wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises the amino acid sequence SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence consisting of SEQ ID NOS: 62 or 64. 
Humanizirano protutijelo koje specifično prepoznaje CD38 naznačeno time što je za upotrebu za liječenje raka koji eksprimira CD38 u kombinaciji barem s bortezomibom, pri čemu je navedeno protutijelo sposobno za ubijanje CD38+ stanica pomoću apoptoze, posredovane citotoksičnosti ovisne o protutijelu (ADCC), te citotoksičnosti ovisne o komplementu (CDC), i pri čemu navedeno protutijelo sadrži barem jedan teški lanac i barem jedan lagani lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline SEQ ID NO: 66, te pri čemu navedeni lagani lanac sadrži sekvencu aminokiseline koja se sastoji od SEQ ID NOS: 62 ili 64.
The humanized antibody specifically recognizing CD38 for use according to claim 12, wherein the hematological cancer is selected from the group consisting of multiple myeloma, leukemia, acute and chronic lymphocytic leukemia, acute and chronic lymphocytic leukemia, acute and chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma; acute and chronic myelogenous leukemias, and promyelocytic leukemia. 
Humanizirano protutijelo koje specifično prepoznaje CD38 za uporabu prema zahtjevu 12, naznačen time što je hematološki karcinom odabran iz skupine koja se sastoji od multiplog mijeloma, leukemije, akutne i kronične limfocitne leukemije, akutne i kronične limfocitne leukemije, akutne i kronične limfoblastne leukemije, limfoma B stanica, limfoma T-stanica, ne-Hodgkinovog limfoma; akutne i kronične mijelogene leukemije, te promijelocitne leukemije.
A pharmaceutical composition comprising a recombinant glycosylated human Serum Amyloid P (SAP) polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with an a2,3-linked sialic acid moiety, and wherein the composition has at least 50% fewer a2,6-linked sialic acid moieties than wild type SAP isolated from human serum. 
Farmaceutski pripravak, naznačen time, da sadržava rekombinantni glikolizirani humani serumski amiloidni P (SAP) polipeptid koji sadržava N-vezani oligosaharidni lanac, pri čemu barem jedna grana oligosaharidnog lanca završava s a2,3-vezanim ostatkom sijalične kiseline i pri čemu smjesa ima najmanje 50% manje a2,6-vezanih ostataka sijalinske kiseline od divljeg tipa SAP izoliranog iz humanog seruma.
The pharmaceutical composition of claim 1, wherein the composition has at least 75%, at least 85%, or at least 95% fewer a2,6-linked sialic acid moieties than wild type SAP isolated from human serum. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da pripravak ima barem 75%, barem 85% ili barem 95% manje a2,6-vezanih ostataka sialne kiseline od divljeg tipa SAP izoliranog iz humanog seruma.
The pharmaceutical composition of any one of claims 1-3, wherein the polypeptide comprises an amino acid sequence that is at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1 or comprises the amino acid sequence of SEQ ID NO: 1. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da polipeptid sadržava sekvencu aminokiselina koja je barem 85%, barem 90%, barem 95% ili barem 99% identična sekvenci aminokiselina od SEQ ID NO: 1 ili sadržava aminokiselinsku sekvencu SEQ ID NO: 1.
The pharmaceutical composition of any one of claims 1-5, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3Galβ4GlcNAcβ2Mana6. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc2a3Galβ4GlcNAcβ2Mana6.
The pharmaceutical composition of any one of claims 1-6, wherein the polypeptide is a fusion protein comprising an SAP domain and one or more heterologous domains. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je polipeptid fuzijski protein koji sadržava SAP domene i jednu ili više heterolognih domena.
A system (10) for producing a molded article, in particular a tray-shaped article (5), from pulp, said system (10) comprising: 
Sustav (10) za proizvodnju lijevanog proizvoda od pulpe, a posebno proizvoda (5) u obliku plitke posude, gdje navedeni sustav (10) sadrži:
a pressing tool (25) having a male mold part (13), and 
alatom (25) za prešanje s muškim dijelom (13) kalupa, i